Consistent with these findings, inhibition of CDK5 reduced tumour growth and improved sensitivity to anti-angiogenic treatment in U87 glioblastoma and Lewis lung carcinoma xenografts [50]. This evidence concerns the gene CDK5 and glioblastoma.